Article Text

Download PDFPDF
Clinical Outcome of Early-Stage Endometroid Adenocarcinoma: A Tertiary Cancer Center Experience
  1. Umesh Mahantshetty, MD, DNB*,
  2. Aditi Aggarwal, MD*,
  3. Balasubramanium Ganesh, PhD,
  4. Sushama Saoba, BSc,
  5. Safoora Mulla, BSc, APGDCR*,
  6. Reena Engineer, DNB*,
  7. Supriya Chopra, MD, DNB*,
  8. Amita Maheshwari, MD,
  9. Rajendra Kerkar, MD, MRCOG,
  10. Shylasree T.S., MD, DNB, MRCOG,
  11. Jaya Ghosh, DM§,
  12. Sudeep Gupta, DM§ and
  13. Shyamkishore Shrivasatava, MD, DNB*
  1. *Departments of Radiation Oncology,
  2. Departments of Medical Records and Epidemiology,
  3. Departments of Surgical Oncology,
  4. §Departments of Medical Oncology, Tata Memorial Center, Mumbai, India.
  1. Address correspondence and reprint requests to Umesh Mahantshetty, MD, DNB, Department of Radiation Oncology, Tata Memorial Hospital, Dr Ernest Borges St, Parel, Mumbai 400012. E-mail: drumeshm@gmail.com.

Abstract

Objective Endometrial cancer (EC) outcome data from developing countries are sparse. We undertook this retrospective analysis to report outcome in our patient population.

Materials and Methods Two hundred forty-nine patients with stage I and II and type I histology ECs referred/treated at our institution from 1998 to 2004 were analyzed. All the details including demographic profile, surgical and histopathological details, as well as International Federation of Gynecology and Obstetrics stage and adjuvant therapy were compiled. The 1988 International Federation of Gynecology and Obstetrics staging and risk stratification were performed on the basis of PORTEC risk groups.

Results With a median age of 54 years (26–72 years), 136 patients (55%) underwent surgery elsewhere; 118 (47.3%) underwent a complete surgical staging. There were 60 (24.1%), 124 (49.8%), 65 (26.1%) patients in the low-risk (LR), intermediate-risk (IR), and high-risk (HR) groups, respectively. Adjuvant radiation was given in 160 patients (LR, 18; IR, 85; and HR, 57). With a median follow-up of 36 months (mean, 40 months), 10 patients had vault recurrences, (LR, 3; IR, 4; and HR, 3), 11 had nodal (5 also had local recurrence; LR, 2; IR, 4; and HR, 5), and 16 had distant recurrences (3 also had nodal; LR, 4; IR, 5; HR, 7). The 5-year disease-free survival (DFS) and overall survival (OAS) rates were 80% and 95%, respectively. The DFS and OAS rates at 5 years were 84% and 97%, 85% and 98%, and 60% and 85% for the LR, IR, and HR groups, respectively. On multivariate analysis, grade (P = 0.002) and type of radiation (P = 0.027) had significant impact on DFS and OAS. Late toxicities (grade 3/4) were vaginal stenosis in 4 (1%) and radiation proctitis in 3 (1%) patients.

Conclusions In our study, ECs are seen in relatively younger population. There is a trend toward incomplete staging surgery outside the oncological referral network. However, the clinical outcome for early-stage type I histology ECs within our population are similar to those reported in the literature.

  • Endometrial cancers
  • Endometroid adenocarcinoma (type I histology)
  • Survivals
  • Prognostic factors
  • Adjuvant radiation

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.